Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.

Despite standard-of-care treatment with renin-angiotensin system inhibitors added to blood pressure and glycaemic control, people with CKD and T1D have a residual risk of CKD progression.

尽管使用肾素-血管紧张素系统抑制剂进行标准治疗，并结合血压和血糖控制，但患有CKD和T1D的人群仍存在CKD进展的残余风险。

Advances in therapeutic management have been limited over the past 3 decades, especially compared with CKD in T2D, for which new treatment options have emerged in the last 5 years.

过去30年里，治疗管理的进步有限，特别是与2型糖尿病相关的慢性肾脏病（CKD）相比，后者在过去5年中出现了新的治疗方案。

In this review article we discuss the similarities and differences between T1D and T2D populations with CKD, including epidemiology, pathophysiology and clinical findings.

在这篇综述文章中，我们将讨论1型糖尿病（T1D）和2型糖尿病（T2D）患者群体中CKD的相似性和差异性，包括流行病学、病理生理学和临床表现。

Additionally, we explore the use of albuminuria as a potential bridging biomarker to extrapolate clinical evidence from one population to the other.

此外，我们探讨了将白蛋白尿作为潜在的桥梁生物标志物，以推断一个群体的临床证据到另一个群体。

This concept could offer a promising strategy to narrow the gap in treatment availability between these populations and address the unmet therapeutic need in people with CKD and T1D.

这一概念可能提供了一个有前景的策略，以缩小这些群体之间治疗可获得性的差距，并解决慢性肾脏病和1型糖尿病患者的未满足治疗需求。

The FINE-ONE trial is investigating the non-steroidal mineralocorticoid receptor antagonist finerenone in a population with CKD and T1D using the change in urine albumin:creatinine ratio from baseline over 6 months as its primary endpoint and bridging biomarker.

FINE-ONE试验正在研究非甾体矿物皮质激素受体拮抗剂finerenone，针对患有慢性肾脏病（CKD）和1型糖尿病（T1D）的人群，以6个月内尿白蛋白：肌酐比值从基线的变化作为其主要终点和桥接生物标志物。

Similarities between the populations from FINE-ONE trial and FIDELITY (a pooled dataset of individuals with CKD and T2D included in two large phase 3 clinical trials of finerenone) may inform the translation of clinical evidence on finerenone from people with CKD and T2D to those with CKD and T1D.

FINE-ONE试验人群与FIDELITY（一个包含在两项大型3期临床试验中的CKD和2型糖尿病（T2D）个体的汇总数据集）之间的相似性，可能有助于将finerenone在CKD和T2D人群中的临床证据转化为CKD和T1D人群的临床证据。